How to Get Repatha (Evolocumab) in Ohio

What Repatha is, and who it is FDA-approved for

Evolocumab is a monoclonal antibody that inhibits PCSK9, a protein that normally degrades LDL receptors in the liver. Blocking PCSK9 keeps more LDL receptors on the liver surface, which pulls more LDL cholesterol out of the blood. The FDA approved evolocumab, marketed as Repatha, in 2015. The current FDA-approved indications are heterozygous or homozygous familial hypercholesterolemia in appropriate patients, and established atherosclerotic cardiovascular disease in adults who need additional LDL-C lowering despite maximally tolerated statin therapy (FDA prescribing information).

Evolocumab is a large protein biologic, not a small-molecule pill, so it is given by injection rather than taken orally. It is not the same molecule as statins, ezetimibe, or bempedoic acid, and it is not interchangeable with alirocumab (Praluent), the other FDA-approved PCSK9 inhibitor, even though the two drugs work by a similar mechanism.

Direct answer with its boundary: Evolocumab (Repatha) is FDA-approved for familial hypercholesterolemia and for ASCVD patients above LDL-C goal on maximally tolerated statin therapy; any Ohio-licensed physician, nurse practitioner, or physician assistant can prescribe it, including through a telehealth visit, but insurer prior authorization documenting prior statin therapy and current LDL-C is the step that actually determines how fast a patient gets the drug. That prior authorization process, along with cash price and specific plan coverage, is date-sensitive and plan-specific, so any number quoted for it should be verified against the current insurer policy rather than treated as fixed.

A 2025 clinical practice guideline on pharmacologic management of dyslipidemia continues to support PCSK9 inhibitors, including evolocumab, as an add-on option for patients who remain above LDL-C goals on statin-based therapy, consistent with earlier cardiology society guidance (2025 AACE dyslipidemia guideline). That guideline-level support is the strongest current evidence anchor for the "who should get this drug" question; the exact LDL-C threshold and required statin trial duration are set by each insurer's own policy, not by a single national rule, and should be confirmed with the specific plan.

Who can prescribe Repatha in Ohio

Ohio does not restrict PCSK9 inhibitor prescribing to cardiologists or lipid specialists. Any Ohio-licensed physician (MD or DO), nurse practitioner with a certificate to prescribe, or physician assistant with an appropriate supervision agreement can write the prescription.

Physicians. Cardiologists, lipidologists, and internal medicine or family medicine physicians all prescribe evolocumab in Ohio when clinically indicated.

Nurse practitioners. Ohio-licensed NPs with a certificate to prescribe may prescribe non-scheduled drugs, which includes evolocumab, under their own prescriptive authority. The scope of that authority is defined in Ohio Revised Code 4723.481 (Ohio Revised Code 4723.481).

Physician assistants. Ohio PAs prescribe under a physician supervision agreement. Evolocumab is not a controlled substance, so it falls within standard PA prescribing scope when the supervision agreement covers cardiovascular or lipid management.

Telehealth prescribers. A synchronous audio-video visit with an Ohio-licensed prescriber can establish the prescriber-patient relationship needed to prescribe evolocumab, because it is a non-controlled biologic and does not carry the in-person exam requirements that apply to some controlled substances. The prescriber still needs to review your labs and history and document a valid clinical basis for the prescription.

What labs a prescriber typically wants before starting Repatha

Before writing the prescription, most Ohio prescribers order a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) to document your current LDL-C, since insurers use that number to judge whether you meet coverage criteria. A basic or comprehensive metabolic panel is commonly checked as well, largely to rule out other conditions rather than because evolocumab requires renal or hepatic dose adjustment; the FDA label does not specify a dose adjustment for renal or hepatic impairment, but any abnormal result should be discussed with your prescriber before starting.

A TSH is often checked because untreated hypothyroidism can raise LDL-C and should be addressed as a contributing cause before adding a PCSK9 inhibitor. Insurers commonly ask for documentation of a prior trial of high-intensity statin therapy, with the specific drug, dose, and duration, or documentation of statin intolerance, because most coverage policies are built around the same guideline logic described above: PCSK9 inhibitors are an add-on for patients who remain above goal on maximally tolerated statin therapy, not a first-line replacement for statins.

Exactly which labs a given insurer requires, and how recent they must be, is a plan-specific detail that changes over time and should be confirmed with your prescriber's office or your insurer rather than assumed.

How prior authorization generally works in Ohio

Prior authorization is the step that most affects how long it takes to get Repatha in Ohio. Ohio-licensed commercial insurers generally require PA for evolocumab, consistent with how most U.S. payers handle high-cost specialty biologics. A typical PA packet includes a completed insurer request form, a letter of medical necessity, a recent fasting lipid panel, documentation of prior statin therapy or intolerance, and documentation of the qualifying diagnosis (a familial hypercholesterolemia diagnosis or evidence of established ASCVD).

Specific PA turnaround windows, appeal rights, and which insurers require what documentation are governed by each payer's own policy and by state and federal insurance regulation that changes periodically. Because those specifics are volatile and plan-dependent, this page does not state exact day counts or name specific Ohio insurers' PA rules as fixed facts. If your PA is denied, Ohio law generally provides for an internal appeal followed by an external independent review; the Ohio Department of Insurance Consumer Services Division can advise on that appeals process, and your insurer's denial letter should include the specific steps and deadlines that apply to your plan.

Amgen has historically operated patient support and co-pay assistance programs for Repatha. Eligibility rules, co-pay amounts, and income thresholds for these programs change and are set by the manufacturer, not by Ohio law, so current details should be confirmed directly with the program rather than assumed from a prior year's terms.

Getting a Repatha prescription through Ohio telehealth

Because evolocumab is a non-controlled biologic, Ohio's telehealth prescribing rules allow a synchronous audio-video visit to serve as the basis for the prescription, without requiring a prior in-person exam. The practical steps are the same regardless of which telehealth platform or in-person office you use:

1. Gather your most recent fasting lipid panel, a list of your statin trials with doses and durations, any cardiac procedure or imaging reports, and your insurance information before the visit.
2. Have the synchronous visit with an Ohio-licensed physician, NP, or PA who reviews your LDL-C trajectory, statin history, and cardiovascular risk.
3. If you meet the prescriber's clinical judgment for evolocumab, the prescription is sent to a specialty pharmacy, since Repatha requires refrigerated handling and is dispensed as a prefilled autoinjector, syringe, or on-body infusor.
4. The specialty pharmacy processes the prior authorization and ships the medication once it is approved.

The total time from visit to first injection depends almost entirely on prior authorization processing, which is plan-specific and not something this page can state as a fixed number.

Repatha dosing basics (not individualized dosing advice)

The FDA label describes two dosing regimens: 140 mg by subcutaneous injection every 2 weeks, or 420 mg by subcutaneous injection once monthly, given as either three consecutive 140 mg injections or a single-use on-body infusor device. Both regimens are approved and are described in trials as producing comparable LDL-C lowering; which one is right for a given patient is a decision for the prescriber, not something to select independently.

Storage matters: the FDA label specifies refrigeration at 36 to 46 degrees Fahrenheit, with a limited allowance for room-temperature storage if refrigeration is not available. Follow the specific instructions provided with your prescription and by your specialty pharmacy rather than general storage rules from any single source.

What the trial evidence shows, and its boundary

A large cardiovascular outcomes trial of evolocumab (commonly known as the FOURIER trial) reported substantial LDL-C reduction when evolocumab was added to statin therapy, along with a reduction in a composite cardiovascular endpoint over roughly two years of follow-up. The exact percentage reductions and hazard ratios reported for that trial should be verified against the primary published study before being quoted as precise figures, since secondary summaries (including earlier versions of this page) have sometimes misstated them.

Separately, a neurocognitive safety substudy of evolocumab found no meaningful difference in cognitive function scores between evolocumab and placebo over extended follow-up. This is reassuring evidence but does not eliminate the need for ordinary clinical monitoring in patients with pre-existing cognitive concerns.

What is established: evolocumab lowers LDL-C substantially when added to statin therapy, and it is FDA-approved for FH and for secondary prevention in ASCVD patients above goal on maximally tolerated statins. What is plausible but not settled by a single page: the exact magnitude of cardiovascular event reduction, since that number depends on trial population and follow-up duration and should be pulled from the primary trial publication, not a secondary summary. What is not established here: any specific Ohio insurer's prior authorization timeline, Ohio Medicaid's current coverage decision for evolocumab, current cash price, or the availability of a biosimilar evolocumab product. These are volatile, plan- and date-specific facts that this page does not have a verified source for as of the last review date, and a reader should confirm them directly with the relevant insurer, pharmacy, or Ohio Medicaid before relying on them.

Compounded evolocumab: a narrow and unusual pathway

Because evolocumab is a biologic monoclonal antibody, it is not a typical candidate for pharmacy compounding in the way small-molecule drugs sometimes are. Ohio-licensed 503A compounding pharmacies operate under Ohio Board of Pharmacy rules and generally may compound a product only for an individual patient with a valid prescription, and not as an essential copy of a commercially available product. Compounding a biologic like evolocumab would be an unusual and narrow scenario, such as a documented excipient allergy that the commercial product cannot accommodate, and it is not a routine or lower-cost access pathway for most patients. Any claim that a 503A pharmacy can broadly substitute for branded Repatha in Ohio should be treated with caution and verified directly with the Ohio Board of Pharmacy and the prescriber before acting on it.

Follow-up and monitoring after starting Repatha

Prescribers typically check a follow-up fasting lipid panel some weeks after starting therapy to confirm response and to support any insurer request for ongoing documentation. Injection site reactions and nasopharyngitis were the most commonly reported adverse effects in trial data, generally at rates similar to or only modestly higher than placebo; serious adverse events were uncommon.

Call your doctor or go to urgent care immediately if you develop signs of a severe allergic reaction to evolocumab such as swelling in your face or throat, trouble breathing, or extensive hives; if your injection site reaction becomes severe or gets worse; or if you notice any new neurological or cognitive changes that worry you, without waiting until your next appointment.

Cost and coverage: what is stable and what changes

Repatha is a high-cost specialty biologic. List price, out-of-pocket cost under a specific insurance plan, Ohio Medicaid's coverage decision, and Medicare Part D formulary placement are all facts that change over time and by plan. This page does not state a specific current price or a specific Ohio Medicaid coverage rule, because those facts require verification against the payer's current published policy rather than a fixed number carried from an earlier version of this article. If cost is a barrier, ask your prescriber's office about manufacturer patient assistance programs and your insurer about your plan's current specialty drug formulary tier.

Verification checklist: what you can treat as stable versus what you must re-check

Use this section to distinguish between stable information about evolocumab from details tied to your insurance coverage, your specific pharmacy, or the current time period that should be confirmed again before making decisions based on them.

Stable, federal or clinical-level facts (safe to treat as generally reliable):

• Evolocumab (Repatha) is FDA-approved for familial hypercholesterolemia and for ASCVD patients above LDL-C goal on maximally tolerated statin therapy.
• Evolocumab is a PCSK9 inhibitor given by subcutaneous injection, either every 2 weeks or monthly per the FDA label.
• Ohio law does not restrict PCSK9 inhibitor prescribing to specialists; physicians, NPs with a certificate to prescribe, and PAs with an appropriate supervision agreement can all prescribe it.
• Evolocumab is not a controlled substance, so Ohio's telehealth rules for non-controlled prescribing generally apply.
• Guideline bodies continue to support PCSK9 inhibitors as an add-on for patients above LDL-C goal on statins.

Date-sensitive facts you must re-verify before acting (do not assume from this page):

• Whether your specific Ohio commercial insurer, Ohio Medicaid managed care plan, or Medicare Part D plan currently covers evolocumab, and under what LDL-C or diagnosis criteria.
• The exact prior authorization documentation and turnaround time required by your plan.
• Current list price and your specific co-pay or patient assistance eligibility.
• Whether a biosimilar or lower-cost alternative to evolocumab has entered the Ohio market as of the date you are reading this.
• Which specialty pharmacies are in-network for your specific plan and how long shipping currently takes.
• Whether the 503A compounding pathway is relevant to your situation at all; for most patients it is not.

If a fact you need falls into the second category, confirm it directly with your insurer, your prescriber's office, or the pharmacy before making a decision based on it.

Transferring an existing Repatha prescription into Ohio

Evolocumab is not a controlled substance, so an existing prescription can generally be transferred between licensed pharmacies within the same state without special restriction. A prescription written by a prescriber who is not licensed in Ohio, however, cannot be filled as a new prescription by an Ohio pharmacy for a new Ohio resident; you will need a new prescription from an Ohio-licensed prescriber, which a telehealth visit can often provide quickly. Prior authorization does not transfer between insurers or states and must be resubmitted to your new Ohio insurer, so bringing your prior lipid labs and any previous PA approval letter can speed that process.